1. Home
  2. LRMR vs XFLT Comparison

LRMR vs XFLT Comparison

Compare LRMR & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

N/A

Current Price

$3.03

Market Cap

253.5M

Sector

Health Care

ML Signal

N/A

Logo XAI Octagon Floating Rate & Alternative Income Term Trust of Beneficial Interest

XFLT

XAI Octagon Floating Rate & Alternative Income Term Trust of Beneficial Interest

N/A

Current Price

$15.91

Market Cap

250.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
LRMR
XFLT
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
253.5M
250.4M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
LRMR
XFLT
Price
$3.03
$15.91
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $14.40
N/A
AVG Volume (30 Days)
★ 1.3M
103.9K
Earning Date
11-24-2026
01-01-0001
Dividend Yield
N/A
★ 14.17%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$3.02
52 Week High
$6.42
$19.63

Technical Indicators

Market Signals
Indicator
LRMR
XFLT
Relative Strength Index (RSI) 59.82 30.06
Support Level $2.89 $15.86
Resistance Level $4.19 $19.53
Average True Range (ATR) 0.25 0.41
MACD 0.09 0.04
Stochastic Oscillator 95.93 12.27

Price Performance

Historical Comparison
LRMR
XFLT

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

About XFLT XAI Octagon Floating Rate & Alternative Income Term Trust of Beneficial Interest

XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.

Share on Social Networks: